Shannon Thyme Klinger

October 17, 2026

Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.

September 30, 2026

Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.